UNSPSC 51351802: Polyestradiol phosphate

This classification denotes a therapeutic estradiol with the molecular formula ((C18H22O3P(C18H22O)n)n(C18H23O4P)n)co, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P14877CDX2, chemically known as 17-beta-estra 1,3,5(10)-triene-3,17-diol, 17-dihydrogen phosphate, homopolymer but generally known as polyestradiol phosphate, which bears US NIH Compound Identifier 66435. European Medicines Agency schedules Polyestradiol phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09973MIG.

UNSPSC 51351802 Polyestradiol phosphate is a Commodity code for pharmaceutical products, though recent state and local procurement activity under this code encompasses broader generic multi-source pharmaceuticals and over-the-counter products rather than the single active pharmaceutical ingredient named in the code. State and local buyers under this code include cooperative purchasing alliances administering multi-state pharmaceutical contracts on behalf of participating state agencies, counties, municipalities, and other public facilities. The work involves supplying finished pharmaceutical products with specific National Drug Codes (NDCs), SKUs, and packaging configurations to authorized wholesaler distribution networks; vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, and demonstrate pricing flexibility through multiple net price and WAC-minus formats. All products must meet FDA requirements, possess expiration dates of at least one year from manufacture with minimum six-month shelf life, and be available in the marketplace by the contract effective date.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The evaluation weights price competitiveness at 75 percent, with fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent) comprising the remainder. Contract awards are effective July 1, 2026 for new responders (two-year initial term) and through June 30, 2028 for incumbents; specific award dollar values are not disclosed. No set-aside designations or restrictions limiting responses to particular business classifications are identified in the available documentation.